Neostigmine® Improves Pancreatic Duct Visualization in Magnetic Resonance Cholangiopancreatography and Could Be a Cheap Alternative for Secretin

Overview

Journal Turk J Gastroenterol

Publisher Aves

Specialty Gastroenterology

Date 2022 Aug 10

PMID 35946885

Authors

Paulina F Toledo

Gonzalo Cardenas

Zoltan Berger

Daniela Simian

Francisca Araya

Affiliations

Soon will be listed here.

Abstract

Background: To determine the effect of intramuscular administration of Neostigmine® on the visualization of the pancreatic duct on magnetic resonance cholangiopancreatography in patients with recurrent acute pancreatitis or abdominal pain.

Methods: We reviewed patients undergoing magnetic resonance cholangiopancreatography followed by a Neostigmine®-enhanced magnetic resonance cholangiopancreatography. Patients with a history of recurrent acute pancreatitis or abdominal pain who had a magnetic resonance cholangiopancreatography where the pancreatic duct was not entirely seen, were selected to undergo a second magnetic resonance cholangiopancreatography 40 minutes after 0.5 mg Neostigmine®. Images were analyzed by 2 radiologists. The diameter of the pancreatic duct was measured in the head, body, and tail of the pancreas on the baseline images and after Neostigmine®.

Results: Ten patients were included, with a median age of 33 years (range 15-61). The maximum diameter of the pancreatic duct increased significantly after Neostigmine® administration in all patients, from 1.84 ± 0.98 to 3.41 ± 1.27 mm in the head, 1.34 ± 0.42 mm to 2.5 ± 0.49 mm in the body and 0.72 ± 0.52 mm to 1.78 ± 0.43 mm in the tail (mean ± SD, P < .0001). Neostigmine® helped to provide better detail of the pancreatic duct anatomy in 4 patients. In 2 patients we confirmed pancreas divisum, in another the Santorini duct was not seen on the baseline images but it was clearly visualized after Neostigmine®, and in the fourth patient, Neostigmine® improved visualization of multiple pancreatic duct stenosis.

Conclusion: Neostigmine®-magnetic resonance cholangiopancreatography significantly increases the diameter of the pancreatic duct, allowing an accurate morphological evaluation. It could be a cheap alternative to secretin, which is expensive and hardly available.

References

Manfredi R, Mucelli R . Secretin-enhanced MR Imaging of the Pancreas. Radiology. 2016; 279(1):29-43. DOI: 10.1148/radiol.2015140622. View

Sica G, Braver J, Cooney M, Miller F, Chai J, Adams D . Comparison of endoscopic retrograde cholangiopancreatography with MR cholangiopancreatography in patients with pancreatitis. Radiology. 1999; 210(3):605-10. DOI: 10.1148/radiology.210.3.r99fe55605. View

Kropil P, Erhardt A, Mehnert S, Beck A, Haussinger D, Modder U . Image quality and bile duct volumetry in MR cholangiopancreatography augmented with low-dose morphine. AJR Am J Roentgenol. 2010; 194(2):W171-5. DOI: 10.2214/AJR.09.3010. View

Nissan N . Modifications of pancreatic diffusion MRI by tissue characteristics: what are we weighting for?. NMR Biomed. 2017; 30(8). DOI: 10.1002/nbm.3728. View

Sherman S, Lehman G . Sphincter of Oddi dysfunction: diagnosis and treatment. JOP. 2002; 2(6):382-400. View

Boraschi P, Donati F, Cervelli R, Pacciardi F . Secretin-stimulated MR cholangiopancreatography: spectrum of findings in pancreatic diseases. Insights Imaging. 2016; 7(6):819-829. PMC: 5110475. DOI: 10.1007/s13244-016-0517-2. View

Patel B . Routine MR Imaging for Pancreas. Magn Reson Imaging Clin N Am. 2018; 26(3):315-322. DOI: 10.1016/j.mric.2018.03.009. View

Agarwal S, Nag P, Sikora S, Prasad T, Kumar S, Gupta R . Fentanyl-augmented MRCP. Abdom Imaging. 2006; 31(5):582-7. DOI: 10.1007/s00261-005-0155-5. View

Madacsy L, Velosy B, Lonovics J, Csernay L . Evaluation of results of the prostigmine-morphine test with quantitative hepatobiliary scintigraphy: a new method for the diagnosis of sphincter of Oddi dyskinesia. Eur J Nucl Med. 1995; 22(3):227-32. DOI: 10.1007/BF01081517. View

10.

Siddiqui N, Vendrami C, Chatterjee A, Miller F . Advanced MR Imaging Techniques for Pancreas Imaging. Magn Reson Imaging Clin N Am. 2018; 26(3):323-344. DOI: 10.1016/j.mric.2018.03.002. View

11.

Silva A, Friese J, Hara A, Liu P . MR cholangiopancreatography: improved ductal distention with intravenous morphine administration. Radiographics. 2004; 24(3):677-87. DOI: 10.1148/rg.243035087. View

12.

Breiman R, Coakley F, Webb E, Ellingson J, Roberts J, Kohr J . CT cholangiography in potential liver donors: effect of premedication with intravenous morphine on biliary caliber and visualization. Radiology. 2008; 247(3):733-7. DOI: 10.1148/radiol.2473070964. View

13.

Tirkes T, Sandrasegaran K, Sanyal R, Sherman S, Schmidt C, Cote G . Secretin-enhanced MR cholangiopancreatography: spectrum of findings. Radiographics. 2013; 33(7):1889-906. DOI: 10.1148/rg.337125014. View

14.

Nardi G, Acosta J . Papillitis as a cause of pancreatitis and abdominal pain: role of evocative test, operative pancreatography and histologic evaluation. Ann Surg. 1966; 164(4):611-21. PMC: 1477319. DOI: 10.1097/00000658-196610000-00008. View

15.

Borghei P, Sokhandon F, Shirkhoda A, Morgan D . Anomalies, anatomic variants, and sources of diagnostic pitfalls in pancreatic imaging. Radiology. 2012; 266(1):28-36. DOI: 10.1148/radiol.12112469. View

16.

Chowdhury A, Humes D, Pritchard S, Marciani L, Gowland P, Simpson J . The effects of morphine-neostigmine and secretin provocation on pancreaticobiliary morphology in healthy subjects: a randomized, double-blind crossover study using serial MRCP. World J Surg. 2011; 35(9):2102-9. DOI: 10.1007/s00268-011-1162-z. View

17.

Dimastromatteo J, Brentnall T, Kelly K . Imaging in pancreatic disease. Nat Rev Gastroenterol Hepatol. 2016; 14(2):97-109. DOI: 10.1038/nrgastro.2016.144. View

18.

Chamokova B, Bastati N, Poetter-Lang S, Bican Y, Hodge J, Schindl M . The clinical value of secretin-enhanced MRCP in the functional and morphological assessment of pancreatic diseases. Br J Radiol. 2017; 91(1084):20170677. PMC: 5966000. DOI: 10.1259/bjr.20170677. View